Aduro Biotech Patent Upheld by USPTO
Published: Nov 10, 2011
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. announces that the United States Patent and Trademark Office (USPTO) has confirmed the patentability of its U.S. Patent 7,842,289 (‘289 patent) at the successful conclusion of an ex parte reexamination proceeding initiated by Advaxis Incorporated (OTCBB: ADXS). During the proceeding, the USPTO rejected Advaxis’ assertions of invalidity, and confirmed that the claims are patentable as originally issued and without amendment. The proceeding has now completed with the issuance of Ex Parte Reexamination Certificate US 7,842,289 C1 on November 1, 2011.